Results 321 to 330 of about 281,052 (341)
Some of the next articles are maybe not open access.
International Journal of Pharmaceutics, 1999
While the search for new antineoplastic agents is in progress, optimization of delivery for existing drugs will remarkably improve the current scenario in the management of cancer. Paclitaxel, a new antineoplastic agent, is one such drug deserving attention in the field of regional drug delivery, offering immense pharmacokinetic as well as therapeutic ...
Anand Babu Dhanikula, Ramesh Panchagnula
openaire +3 more sources
While the search for new antineoplastic agents is in progress, optimization of delivery for existing drugs will remarkably improve the current scenario in the management of cancer. Paclitaxel, a new antineoplastic agent, is one such drug deserving attention in the field of regional drug delivery, offering immense pharmacokinetic as well as therapeutic ...
Anand Babu Dhanikula, Ramesh Panchagnula
openaire +3 more sources
Clinical Pharmacokinetics of Paclitaxel
Clinical Pharmacokinetics, 1994Paclitaxel is a new anticancer agent showing significant promise as therapy for solid tumours and leukaemia, given alone or in combination with other chemotherapeutic agents. Paclitaxel concentrations in biological specimens can be measured using high performance liquid chromatography, or more recently by immunoassay.
Daryl Sonnichsen +3 more
openaire +3 more sources
Future Cardiology, 2006
Percutaneous coronary intervention and stent implantation is rapidly becoming the most commonly used form of revascularization. The long term results of this procedure are limited by restenosis which is a phenomenon predominantly caused by proliferation of smooth muscle cells.
Simon Corbett +3 more
openaire +3 more sources
Percutaneous coronary intervention and stent implantation is rapidly becoming the most commonly used form of revascularization. The long term results of this procedure are limited by restenosis which is a phenomenon predominantly caused by proliferation of smooth muscle cells.
Simon Corbett +3 more
openaire +3 more sources
Cancer Investigation, 1997
We appreciate Mr. Hill's comments (Cancer Investigation 14(6):644, 1996) concerning the listing of hypertension in the manufacturer's insert for paclitaxel. We made reference to the (since revised) 1993 insert in our original report because, when it was accepted for publication, that was the current version.
Dominic A. Solimando, Raymond B. Weiss
openaire +2 more sources
We appreciate Mr. Hill's comments (Cancer Investigation 14(6):644, 1996) concerning the listing of hypertension in the manufacturer's insert for paclitaxel. We made reference to the (since revised) 1993 insert in our original report because, when it was accepted for publication, that was the current version.
Dominic A. Solimando, Raymond B. Weiss
openaire +2 more sources
Gemcitabine combined with paclitaxel or paclitaxel/trastuzumab in metastatic breast cancer
Seminars in Oncology, 2003The combination of gemcitabine and paclitaxel in metastatic breast cancer is attractive because of the good single-agent activity of each, the different mechanisms of antitumor effect, and the, generally, nonoverlapping toxicity profiles of the agents.
openaire +3 more sources
Individualized pharmacotherapy with paclitaxel
Current Opinion in Oncology, 2007More than two decades of clinical experience with paclitaxel as an anticancer drug have contributed significantly to the optimization of today's application schemes and patients' safety. Recent knowledge about interindividual pharmacokinetic variability and population modeling provides a novel scientific basis for an improved and individualized ...
openaire +3 more sources
Overview of Paclitaxel (TAXOL®)
Seminars in Oncology Nursing, 1993The history of development of paclitaxel (TAXOL [Bristol-Myers Squibb Co., Princeton, NJ]) is a long story and serves as a model of perseverance for those involved in drug development. Notations of the use of products of the yew tree date back to the Celts, but it was in the 1950s to the 1960s that the National Cancer Institute (NCI) selected the ...
openaire +3 more sources
Pharmacogenetics of paclitaxel metabolism
Critical Reviews in Oncology/Hematology, 2007Paclitaxel is one of the most widely used and effective anticancer drugs. Paclitaxel's clinical utility spans many tumor sites, including treatment of ovarian, breast, lung, head and neck, and unknown primary cancers. As is the case with most chemotherapy drugs, paclitaxel is administered empirically with little individualization of dose other than ...
Jennifer L. Spratlin, Michael B. Sawyer
openaire +3 more sources
A facile N-debenzoylation of paclitaxel: Conversion of paclitaxel to docetaxel
Tetrahedron Letters, 1999AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.
Prakash Jagtap, David G. I. Kingston
openaire +3 more sources
Pharmacology and Pharmacokinetics of Paclitaxel
Annals of Pharmacotherapy, 1994There remain several pharmacologic considerations relating to paclitaxel that are being, or need to be, explored. Some of the more important of these include the following issues: Further elaboration of the metabolic fate of paclitaxel. A multicenter study is currently being planned to determine the complete metabolic fate of paclitaxel, using ...
openaire +2 more sources